Department of Pharmaceutics, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences and Healthcare Services, Yazd, Iran.
Department of Prosthodontics, Faculty of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
BMC Oral Health. 2024 May 11;24(1):551. doi: 10.1186/s12903-024-04322-6.
Periodontal diseases may benefit more from topical treatments with nanoparticles rather than systemic treatments due to advantages such as higher stability and controlled release profile. This study investigated the preparation and characterization of thermosensitive gel formulations containing clindamycin-loaded niosomes and solid lipid nanoparticles (SLNs) loaded with fluconazole (FLZ), as well as their in vitro antibacterial and antifungal effects in the treatment of common microorganisms that cause periodontal diseases.
This study loaded niosomes and SLNs with clindamycin and FLZ, respectively, and assessed their loading efficiency, particle size, and zeta potential. The particles were characterized using a variety of methods such as differential scanning calorimetry (DSC), dynamic light scattering (DLS), and Transmission Electron Microscopy (TEM). Thermosensitive gels were formulated by combining these particles and their viscosity, gelation temperature, in-vitro release profile, as well as antibacterial and antifungal effects were evaluated.
Both types of these nanoparticles were found to be spherical (TEM) with a mean particle size of 243.03 nm in niosomes and 171.97 nm in SLNs (DLS), and respective zeta potentials of -23.3 and -15. The loading rate was 98% in niosomes and 51% in SLNs. The release profiles of niosomal formulations were slower than those of the SLNs. Both formulations allowed the release of the drug by first-order kinetic. Additionally, the gel formulation presented a slower release of both drugs compared to niosomes and SLNs suspensions.
Thermosensitive gels containing clindamycin-loaded niosomes and/or FLZ-SLNs were found to effectively fight the periodontitis-causing bacteria and fungi.
由于稳定性更高和更可控的释放特性等优势，牙周病可能更受益于纳米颗粒的局部治疗而非全身治疗。本研究旨在制备和表征包含克林霉素载药纳米囊泡和载氟康唑固体脂质纳米粒（SLN）的温敏凝胶制剂，并研究其在治疗常见牙周病致病菌中的体外抗菌和抗真菌效果。
本研究分别将纳米囊泡和 SLN 载药克林霉素和氟康唑，并评估其载药效率、粒径和 Zeta 电位。通过差示扫描量热法（DSC）、动态光散射（DLS）和透射电子显微镜（TEM）等多种方法对载药纳米粒进行表征。通过将这些纳米粒与温敏凝胶制剂结合，评估其黏度、胶凝温度、体外释放特性以及抗菌和抗真菌效果。
两种纳米粒均为球形（TEM），纳米囊泡的平均粒径为 243.03nm（DLS），Zeta 电位为-23.3mV；SLN 的平均粒径为 171.97nm（DLS），Zeta 电位为-15.0mV。纳米囊泡的载药率为 98%，而 SLN 的载药率为 51%。纳米囊泡制剂的释放曲线比 SLN 制剂更慢。两种制剂均符合一级动力学药物释放特征。此外，与纳米囊泡和 SLN 混悬液相比，凝胶制剂中两种药物的释放速度更慢。
含克林霉素载药纳米囊泡和/或氟康唑载药 SLN 的温敏凝胶制剂可有效对抗引起牙周病的细菌和真菌。
